Application of Single-Use Technologies in Medical Countermeasure Development & Manufacturing for Emerging Pathogens
|
|
- Gilbert Sullivan
- 5 years ago
- Views:
Transcription
1 Application of Single-Use Technologies in Medical Countermeasure Development & Manufacturing for Emerging Pathogens BPSA s 7 th Annual Int l Single-Use Summit July 13, 2017 Mike Angelastro Director (acting), BARDA Division of Manufacturing, Facilities & Engineering
2 Outline BARDA 101 What, why & how is BARDA? CIADM Program Update from 2012 Adoption of single-use Q&A 2
3 Introduce Some Acronyms (ISA) U.S. Department of Health & Human Services (HHS) Assistant Secretary for Preparedness & Response (ASPR) Biomedical Advanced Research & Development Authority (BARDA) Chemical, Biological, Radiological & Nuclear Threats (CBRN) Medical Counter-measures (MCM) Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Centers for Innovation in Advanced Development & Manufacturing (CIADM) 3
4 BARDA Origins In existence since 2004 under predecessor organizations Project BioShield Act of 2004, provided funding under the Special Reserve Fund (SRF) 2005 National Strategy for Pandemic Influenza for federal agencies pandemic response Dec 2006 Pandemic & All-Hazards Preparedness Act (PAHPA), and Mar 2013 Pandemic & All-Hazards Preparedness Reauthorization Act (PAHPRA) 4
5 BARDA Mission Support the advanced development of and make available medical countermeasures (MCMs) for Chemical, Biological, Radiological & Nuclear (CBRN) threats, pandemic influenza and emerging infectious diseases by transitioning candidates from early development across the Valley of Death into advanced development to regulatory approval O Neill Building Washington, DC 5
6 ? Medical Countermeasures? BARDA develops medical countermeasures (MCMs) by forming public-privatepartnerships with biotechnology and industry partners Vaccines Therapeutics Diagnostics 6
7 BARDA Organization HHS ASPR Secretary Tom Price, MD ASPR (acting) George Korch, PhD Biomedical Advanced Research & Development Authority (BARDA) Division of Chemical, Biological, Radiological & Nuclear (CBRN) Influenza & Emerging Diseases (IED) Division Office of the Director Rick Bright, PhD Division of Quantitative Analysis (DQA) Division of Regulatory & Quality Affairs (RQA) Manufacturing, Facilities & Engineering (MFE) Division Diagnostics & Medical Devices (DMD) Division Division of Clinical Studies (DCS) 7
8 BARDA MCMs Transistions, in general (1) Early research & development efforts supported by NIH, DoD, industry, academic labs (2) Advanced research & development (ARD) supported by BARDA for HHS [CMS for DoD] Typically after completion of Phase I ARD supports the data necessary for potential use of the MCM during a declared emergency Criteria for inclusion of a product into the SNS formulary Emergency Use Authorization (EUA) (3) Project BioShield (PBS) Support late-stage development and procurement Pivotal clinical and non-clinical studies and validation of the manufacturing process Once licensed/ approved transitioned to CDC SNS for maintenance 8
9 PRODUCT PIPELINE Why BARDA? Vaccine & Drug Development: Expensive, Risky, and Lengthy PHASES Preclinical Development IND NDA/BLA Discovery Phase I Phase II Phase III Licensure Production & Delivery NIH, CDC NIH & ($11.8B) DoD Valley of Death BARDA ($540M) Project Project Bioshield/ BioShield CDC s ($5.6B) SNS MERS-COV ZIKA EBOLA % 5-17% 10-25% 18-35% 45-70% 90% PROBABILITY OF SUCCESS TO LICENSURE Licensed Product TIME PIPELINE PHASE COST 3-7 yr yr 1-2 yr yr yr 1-2 yrs $100M -130M $60-70M $70M-100M $130M-160M $190M-220M $18M-20M 9
10 Public Health Emeregency Medical Countermeasure Enterprise 10
11 Stakeholder Collaborations 11
12 BARDA Today Track record 27 products cleared, approved or licensed since products procured for the nation s SNS Our mission is evolving Emerging infectious diseases (Ebola, MERS, Zika) Combatting antibiotic resistant bacteria New initiatives in traditional domains: Blood products, influenza therapeutics and vaccines, chemical threats, diagnostics We are increasingly flexible in how we partner Traditional contracts & cooperative agreements [very few grants] Portfolio partnerships (Continuous Manufacturing w/ FDA) Partnerships centered on BARDA s core services (i.e. CIADM) Non-traditional contracting (i.e. CARB-X Contract) 12
13 BARDA Core Services RQA CSN Clinical Studies Network 2014 Regulatory & Quality Affairs ADS Analytical Decision Support FFMN Fill & Finish Manufacturing Network CIADM 2011 NSN Nonclinical Services Network Centers for Innovation in Advanced Development & Manufacturing 13
14 Centers for Innovation in Advanced Development & Manufacturing (CIADM) 14
15 HHS CIADM Core Service Network 15
16 As Envisioned Complimentary Capabilities Contracts Awarded June 2012 up to 25 years 16
17 HHS CIADM Domestic Surge Capability As Envisioned To Close Capacity Gap 3 Awards made Each delivers 50M doses if influenza vaccine within 4 months 1 st doses delivered by week 12 Capacity Gap 150M Influenza Vaccine Doses Other Use for Increased Vaccine Capacity Moderate/ Large scale biopharmaceutical manufacturing to support MCM candidates for select emerging infectious diseases 3 awards made to address capacity gap that existed with pandemic influenza response 17
18 Seqirus CIADM Holly Springs, NC First cell-based influenza vaccine manufacturing facility in the U.S. 18
19 Seqirus CIADM Holly Springs, NC Clinical Scale cgmp Fill & Finish (including lyo) Capability 19
20 TAMUS CIADM College Station, TX Mobile Clean Rooms (MCRs) 20
21 TAMUS CIADM College Station, TX National Center for Therapeutics Manufacturing (NCTM) 21
22 TAMUS CIADM College Station, TX Inside the Mobile Clean Room (MCR) 22
23 TAMUS CIADM College Station, TX Multiproduct Facility [mabs, Live Virus] 23
24 Emergent BioSolutions CIADM Baltimore, MD 24
25 Emergent BioSolutions CIADM Baltimore, MD Ribbon Cutting May ,000 sq-ft manufacturing facility purchased in 2009 by Emergent Bayview Manufacturing Facility Retrofit & construction created three fully segregated manufacturing areas, QC Labs, administrative space & (future) cgmp pilot operation Three ~9,000 sq-ft cgmp suites, each with two 2,000 Liter SUB trains Infrastructure and experience to manufacture vaccines and therapeutics 25
26 Emergent BioSolutions CIADM Baltimore, MD Facility Design Multi-product Manufacturing Live viral vaccines Cell culture Microbial Segregation Floor-to-ceiling dividing wall Segregated utilities Segregated HVAC w/ low-wall returns Segregated drains and waste flows 26
27 Emergent BioSolutions CIADM Baltimore, MD Single-use Bioreactor Platform ( L) 27
28 Emergent BioSolutions CIADM Baltimore, MD Depth filters for clarification Jacketed and un-jacketed single-use mixers range from 50 L to 1000 L 28
29 Emergent BioSolutions CIADM Baltimore, MD Pre-packed columns (up to ~50 cm) Single-use Tangential Flow Filtration (TFF) 29
30 DoD s NANO-ADM Alachua, FL NanoADM facility was built by Nanotherapeutics Inc. and is Contractor-owned, contractor-operated (COCO) enterprise DoD s JPM-MCS procured and installed specialized single-use modular pharmaceutical manufacturing equipment 30
31 Whole of Government Approach DoD NANO-ADM HHS CIADM Focused on global threats Supports 1.4M service members 18 to 55 years old Works toward a state of good health Maintains broad product portfolio to protect service members Produces small force to full force scale depending on threat Focused on threats to the homeland Supports U.S. population pediatrics to geriatric Works on the entire health continuum Maintains a vaccine-focused pandemic flu portfolio Produces relatively large scale to support the entire U.S. population. 31
32 DoD s NANO-ADM Alachua, FL A 180,000 sq ft. cgmp biologics manufacturing facility Two BSL-3 cgmp upstream/downstream/media areas 32
33 DoD s NANO-ADM Alachua, FL Facilitates S&T Supports pilot-scale through cgmp large-scale manufacturing for development and sustainment Designed for Biosafety Level 3 (BSL-3) manufacturing Utilizes single-use technologies Implements agile manufacturing strategies 33
34 Contacting BARDA Announcements Requests for Information (RFI) & Proposals (RFP) Broad Agency Announcements (BAAs) To request a Tech Watch meeting Michael.Angelastro@hhs.gov Director (acting) BARDA s Division of Manufacturing, Facilities & Engineering 34
35 BARDA Endorsements Medical CBRN Defense Consortium (MCDC) Currently recruiting collective expertise in the technology areas specifically related to the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) mission. 35
36 BARDA Endorsements Also recruiting The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) A public-private consortium dedicated to advancing biopharmaceutical manufacturing innovation 36
OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES
OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES Dr. Robert P. Kadlec Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services 2017 Chemical and
More informationPROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE
PROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE Gerald R. Kovacs, PhD Director, Division of Chem/Bio/Rad/Nuc Medical Countermeasures Biomedical Advanced Research and Development Authority Assistant
More informationSuccessful Collaboration and Preparedness in Global Governance
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Successful Collaboration and Preparedness in Global Governance ISARIC meeting London,
More informationEmergency Use Authorizations
Emergency Use Authorizations May 26, 2016 Quality Improvement Forum Call Celia Hagan, MPH Senior Specialist, Public Policy Overview Emergency Use Authorization (EUA) authority EUA issuance process Zika
More informationTESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY, BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO)
TESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY, BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) SENATE HELP COMMITTEE May 17, 2011 Good morning Chairman
More informationBARDA s Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures
BARDA s Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures Joe Larsen, Ph.D. Director (Acting) BARDA Division of CBRN Medical Countermeasures January 2018 ASPR: Saving Lives
More information8/3/2016 THE BARDA CHEMICAL/RADIOLOGICAL/NUCLEAR COUNTERMEASURES EFFORT. Biodefense MCM History
THE BARDA CHEMICAL/RADIOLOGICAL/NUCLEAR COUNTERMEASURES EFFORT Tom C.-C. Hu, Ph.D. MBA DABMP Interdisciplinary Scientist/Project Officer US Department of Health and Human Services Office of the Assistant
More informationBARDA INDUSTRY DAYS 10 th Anniversary November 7-8, 2017
BARDA INDUSTRY DAYS 10 th Anniversary November 7-8, 2017 Below is a summary of the BARDA Industry Days Conference in D.C. November 7-8, 2017. Each year this conference is organized by the Biomedical Advanced
More informationFinancing Influenza Vaccine R&D
Financing Influenza Vaccine R&D WHO GAP-II Geneve, Switzerland July 13, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary & Director HHS/ASPR/BARDA 0 Vaccine Development is Risky, Lengthy, & Expensive
More informationAdvancements in CBRN Medical Countermeasures
Advancements in CBRN Medical Countermeasures Gerald R. Kovacs, Ph.D. Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Presentation at the MARCE Public Health Emergency
More informationOPTIMIZING INDUSTRIAL INVOLVEMENT WITH MEDICAL COUNTERMEASURE DEVELOPMENT: Washington, DC February 22, 2010
OPTIMIZING INDUSTRIAL INVOLVEMENT WITH MEDICAL COUNTERMEASURE DEVELOPMENT: A REPORT OF THE NATIONAL BIODEFENSE SCIENCE BOARD www.hhs.gov/aspr/omsph/nbsb/ Washington, DC February 22, 2010 The National Biodefense
More informationProduct Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
More informationTowards a Sustainable Global Infrastructure for Medical Countermeasures
Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from
More informationMEDICAL AND PUBLIC HEALTH PREPAREDNESS AND RESPONSE: ARE WE READY FOR FUTURE THREATS?
FEBRUARY 26, 2015 MEDICAL AND PUBLIC HEALTH PREPAREDNESS AND RESPONSE: ARE WE READY FOR FUTURE THREATS? U.S. SENATE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS ONE HUNDRED FOURTEENTH CONGRESS,
More informationU.S. Readiness for Pandemics
0 U.S. Readiness for Pandemics 5 th National Emergency Management Summit Brooklyn, NY September 15, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary for Preparedness & Response (HHS/ASPR) Director
More informationBiopharma's Flexible Imperative. Robert Dream Principal, HDR COMPANY LLC April 24, 2013
Biopharma's Flexible Imperative Robert Dream Principal, HDR COMPANY LLC April 24, 2013 Biopharma's Flexible Imperative Introduction Can history help us see the future Comparing 1918 and today Pandemic
More informationDevelopment and Procurement of Biotechnology for Emerging Disease and Engineered Threats in the Public Health Preparedness Sector
Development and Procurement of Biotechnology for Emerging Disease and Engineered Threats in the Public Health Preparedness Sector John M. Clerici john@tibercreekpartners.com Public Health Preparedness
More informationVaccine Innovation and Adult Immunization Landscape
Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org
More informationThe EUA Process at CDC Michael W. Shaw, PhD
The EUA Process at CDC Michael W. Shaw, PhD Office of Infectious Diseases DECLARATION OF EMERGENCY OR THREAT JUSTIFYING EMERGENCY USE Before FDA may issue an EUA, the HHS Secretary must declare that circumstances
More informationCPRIT Overview. Cancer Centers Administrators Forum April 4, 2016
CPRIT Overview Cancer Centers Administrators Forum April 4, 2016 CPRIT s Unique Role in the Fight Against Cancer Overview: Created by the Texas Legislature and citizens in 2007 $3 billion over 10 years
More informationEC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
More informationAppendix 3: Federal Government Agencies Involved in Immunization
Appendix 3: Federal Government Agencies Involved in Immunization Department of Health and Human Services (HHS) Secretary of Health and Human Services Directs all HHS activities. Office of the Assistant
More informationPage 1 of 5 For Immediate Release Office of the Press Secretary July 17, 2007 Fact Sheet: Implementation of the National Strategy for Pandemic Influenza A One-Year Summary Of Efforts To Better Protect
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in
Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education
More informationPublic Safety and Health Cooperation from the Canadian Perspective
1 2 Public Safety and Health Cooperation from the Canadian Perspective Presentation by: Dr. Rainer Engelhardt Assistant Deputy Minister Infectious Disease Prevention and Control Public Health Agency of
More informationRe: Trust for America s Health Comments on Biennial Implementation Plan for the National Health Security Strategy
Dr. Nicole Lurie, MD, MSPH Assistant Secretary for Preparedness & Response Department of Health and Human Services Washington, DC 20201 Re: Trust for America s Health Comments on Biennial Implementation
More informationPrepared for Members and Committees of Congress
Prepared for Members and Committees of Congress Œ œ Ÿ Many potential chemical, biological, radiological, and nuclear (CBRN) terrorism agents lack available countermeasures. In 2003, President Bush proposed
More informationApproaches to Pandemic Influenza Vaccine Preparedness
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Approaches to Pandemic Influenza Vaccine Preparedness Julie Schafer, MPH, MS Influenza
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More informationCDC Strategies to Strengthen Public Health Emergency Management Programs
CDC Strategies to Strengthen Public Health Emergency Management Programs Christine Kosmos, R.N., B.S.N., M.S. Director, CDC Division of State and Local Readiness ASTHO Eleventh Annual DPHP Meeting October
More informationCDC s Global Disease Detection Program
CDC s Global Disease Program Scott F. Dowell, MD, MPH Division of Global Disease and Emergency Response Centers for Disease Control and Prevention Rationale for Global Disease It would be extremely naïve
More informationMEDICAL PRODUCTS FOR PUBLIC HEALTH EMERGENCIES GEORGE W. KORCH, JR. PHD ACTING ASSISTANT SECRETARY
MEDICAL PRODUCTS FOR PUBLIC HEALTH EMERGENCIES GEORGE W. KORCH, JR. PHD ACTING ASSISTANT SECRETARY National defense industry association CBRN Conference 15 August 2017 ASPR brings together policy, science,
More informationOpportunities for the Future of Healthcare and Public Health Preparedness, Response, and Recovery
Opportunities for the Future of Healthcare and Public Health Preparedness, Response, and Recovery National Academy of Medicine Workshop March 8-9, 2017 Tom Inglesby Healthcare system that can care for
More informationManaging cost considerations and access to technology for cost effective vaccine manufacture in developing countries.
Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities
More informationAnti-Viral Prophylaxis Target Product Profile Guidelines
Anti-Viral Prophylaxis Target Product Profile Guidelines February 24, 2009 Report Documentation Page Form Approved OMB No. 0704-0188 Public reporting burden for the collection of information is estimated
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationPresident's FY 2009 Budget Request for R&D and Public Health Programs
Request for R&D and Public Health Programs (in millions) : http://www.whitehouse.gov/omb/budget/fy2007/ FY Final Appropriations: http://thomas.loc.gov/home/approp/app08.html FY Levels based on Documents
More informationFY 2008 Appropriations for R&D and Public Health Programs (in millions)
FY 2008 Appropriations for R&D and Public Health Programs (in millions) AGENCY PROGRAM FY 2008 Appropriations Status: http://thomas.loc.gov/home/approp/app08.html FY 2008 : http://www.whitehouse.gov/omb/budget/fy2007/
More informationMark R. Wilson, Ph.D. Chemical Biological Sciences Unit FBI Laboratory
Forensic Issues Regarding the Analysis of Evidence in Support of Agroterrorism Investigations Mark R. Wilson, Ph.D. Chemical Biological Sciences Unit FBI Laboratory 703-632-7770 mwilson@fbiacademy.edu
More informationLabor, Health and Human Services & Education Labor, Health and Human Services & Education
October 7, 2016 The Honorable Harold Rogers, Chairman The Honorable Nita Lowey, Ranking Member House Appropriations Committee House Appropriations Committee Washington, DC 20515 Washington, DC 20515 The
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL INTERIM REPORT 02_2013
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EXECUTIVE AGENCY FOR HEALTH AND CONSUMERS Health unit Contract number: 2010 21 02 Acronym: QUANDHIP INTERIM REPORT 02_2013 Proposal title: Quality
More informationUpdate of The National Vaccine Plan
Update of The National Vaccine Plan Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human Services Presentation Outline Statutory basis for the National Vaccine Program
More informationFY2019 Labor, Health and Human Services, Education Appropriations Summary
Labor, Health and Human Services, Education Appropriations Summary NACCHO Priority Public Health Program Funding The Senate Appropriations Committee marked-up a bill funding the Departments of Labor, Health
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationBusiness Continuity and Crisis Management. Cardinal Health s Approach
Business Continuity and Crisis Management Cardinal Health s Approach Welcome We don t have ALL the answers Opportunity to share ideas Discussion around how we can work together to help prepare our communities,
More informationUSG Policy Perspectives on Global Influenza
USG Policy Perspectives on Global Influenza IOM Committee for the Assessment of DoD-GEIS Influenza Surveillance & Response Programs Ms. Ellen P. Embrey Deputy Assistant Secretary of Defense Force Health
More informationUSDA APHIS One Health Initiative
Biorisk Management in a One Health World USDA APHIS One Health Initiative Joseph F. Annelli, DVM, MS One Health Coordination Center U.S. Department of Agriculture Animal and Plant Health Inspection Service
More informationEstablishing human vaccine manufacturing in Southern Africa
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-21-2012 Establishing human vaccine manufacturing in Southern Africa Morena Makhoana The Biovac Institue
More informationAn Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)
An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines
More informationFY2019 Labor, Health and Human Services, Education Appropriations Summary
Labor, Health and Human Services, Education Appropriations Summary NACCHO Priority Public Health Program Funding On June 25, the House Appropriations Committee released a draft bill and accompanying report
More informationTestimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and
Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and The Society for Healthcare Epidemiology of America (SHEA) to the U.S. House of Representatives Appropriations
More informationMichel BAIJOT Vice President, WW Business Development & Strategic Alliances
Technology Transfer and Vaccines: The GSK Experience WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Geneva, November 30th, 2010 Michel BAIJOT Vice President, WW Business
More informationPublic Health Emergency Preparedness: Looking Back, Moving Forward U.S. Efforts and International Dimensions
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Public Health Emergency Preparedness: Looking Back, Moving Forward U.S. Efforts and International
More informationNIAID Biodefense Research Agenda
NIAID Biodefense Research Agenda Deborah G. Katz, M.S., R.N. Deputy Director Office of Biodefense Research Affairs National Institute of Allergy and Infectious Diseases Princeton University September 8,
More information7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities
7th Mena Influenza Stakeholders Meeting WHO Influenza Strategy Development and Vaccine-related Research Priorities Wenqing Zhang 9 10 September 2017 Riga, Latvia 1 Seasonal influenza 1 billion cases yearly
More informationMedical Countermeasures for Children in Public Health Emergencies, Disasters, or Terrorism DISASTER PREPAREDNESS ADVISORY COUNCIL
POLICY STATEMENT Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children Medical Countermeasures for Children in Public Health Emergencies,
More information9/14/12. IDSA Pandemic and Seasonal Influenza: Principles for U.S. Action. Prediction is very difficult, especially about the future
IDSA Pandemic and Seasonal Influenza: Principles for U.S. Action Andrew T. Pavia M.D. Chair IDSA Pandemic Influenza Task Force George and Esther Gross Presidential Professor Chief Division of Pediatric
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More information2009-H1N1 Pandemic Influenza: DHS Perspective
2009-H1N1 Pandemic Influenza: DHS Perspective Terry Adirim, MD, MPH Senior Advisor for Science and Public Health Office of Health Affairs U.S. Department of Homeland Security The National Emergency Management
More informationThe Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework
The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework A position paper from the Directors of the GISRS WHO Collaborating
More informationIncreasing Adult Immunization Rates in the US Through Data and Quality: A Roadmap
Increasing Adult Immunization Rates in the US Through Data and Quality: A Roadmap Avalere Health An Inovalon Company November 16, 2017 In Partnership with GSK Agenda 1 2 3 4 5 Welcome & Introductions Overview:
More informationScience. Systems Policy Process Programs People
Expectations Bioterrorism - a real and present danger Anthrax attacks in the United States, 2001 Time Where to Implement Are Changes We and? Unexpected Consequences f Science Systems Policy Process Programs
More informationCenter for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home
Center for Global Health CDC Global Health Saving Lives Overseas, Protecting Americans at Home CDC Overview Part of the U.S. Department of Health and Human Services, CDC is the nation s leading public
More information1201 Maryland Avenue SW Suite 900 Washington, DC
June 14, 2012 Lonnie King, D.V.M. Chair Committee on Identifying and Prioritizing New Preventive Vaccines for Development Institute of Medicine 500 Fifth Street, NW Washington, DC 20001 Re: Ranking Vaccines:
More informationWorking with US and International Partners to Strengthen Preparedness & Response at the Domestic-International Interface
How can the U.S. efforts in international public health disaster and emergency response strengthened and who should take the lead? Working with US and International Partners to Strengthen Preparedness
More informationBoehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider
Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:
More informationPlanning for Pandemic Influenza in York County: Considerations for Healthcare and Medical Response
Planning for Pandemic Influenza in York County: Considerations for Healthcare and Medical Response York County Pandemic Influenza Stakeholders Village by the Sea, Wells, Maine 8 August 2006 Steven J Trockman,
More informationAssessment of Influenza Vaccine Production Compatibilities
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza
More informationPandemic Influenza Preparedness Framework. Sharing influenza viruses & access to vaccines and other benefits
Pandemic Influenza Preparedness Framework Sharing influenza viruses & access to vaccines and other benefits What is PIP? Landmark, innovative public health arrangement to increase global preparedness to
More informationAnnual Meeting June 7, 2011
Annual Meeting June 7, 2011 1 Safe Harbor This presentation includes forward looking statements and predictions, including statements about potential revenue bearing transactions, the market potential
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationManagement Presentation. January 2019
Management Presentation January 2019 Forward Looking Statements The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirusinfections,
More informationGAO INFLUENZA PANDEMIC. Lessons from the H1N1 Pandemic Should Be Incorporated into Future Planning. Report to Congressional Requesters
GAO United States Government Accountability Office Report to Congressional Requesters June 2011 INFLUENZA PANDEMIC Lessons from the H1N1 Pandemic Should Be Incorporated into Future Planning GAO-11-632
More informationCDC Prepares Special Issue August 2006
CDC Prepares Special Issue August 2006 Fast Facts CDC s Influenza Pandemic Operation Plan The final draft of CDC s Influenza Pandemic Operation Plan has been completed and includes more than 1600 specific
More informationRoles and Responsibilities
Prior to the declaration of a public health emergency, State and local planners should examine existing State public health and medical licensing laws, interstate emergency management compacts and mutual
More informationConversation with Tom Inglesby on October 2, 2013
Participants Conversation with Tom Inglesby on October 2, 2013 Tom Inglesby, M.D., Chief Executive Officer and Director, University of Pittsburgh Medical Center (UPMC) Center for Health Security Alexander
More informationBiomanufacturing Training and Education Center (BTEC) s International Influenza Vaccine Manufacturing Training Program
Biomanufacturing Training and Education Center (BTEC) s International Influenza Vaccine Manufacturing Training Program 5 th Meeting with International Partners on Prospects for Influenza Vaccine Manufacturing
More informationThe Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
More informationPublic Health Emergencies: Mass Dispensing in the Community
Public Health Emergencies: Mass Dispensing in the Community Chrissy Gamboa - Pinal County Public Health Chris Lyons, RN - Maricopa County Public Health Role of Public Health in an Disease prevention Emergency
More informationREPORT TO CONGRESS Multi-Disciplinary Brain Research and Data Sharing Efforts September 2013 The estimated cost of report or study for the Department of Defense is approximately $2,540 for the 2013 Fiscal
More informationEuropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) Health in Europe: A Strategic Approach
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Health in Europe: A Strategic Approach Comments by the ESCMID Executive Committee, http://www.escmid.org The European Society
More informationPreparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do
Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do Based on current data and information from the Centers for Disease Control (CDC) and the U.S. Department Health and Human Services
More informationQuestions and Answers Regarding Federal Contracts for State-Purchased Antiviral Drugs (Relenza & Tamiflu ) (07/26/06)
Questions and Answers Regarding Federal Contracts for State-Purchased Antiviral Drugs (Relenza & Tamiflu ) (07/26/06) These questions were received in response to the recently executed contracts with Roche
More informationRequest for Letters of Intent. International Development of H5N1 Influenza Vaccines
Request for Letters of Intent International Development of H5N1 Influenza Vaccines The World Health Organization (WHO) intends to provide funding to developing (1) country vaccine manufacturers to develop
More informationPandemic Influenza Cross Sectoral Preparedness and Planning
Opening statement Seminar on Pandemic Influenza Cross Sectoral Preparedness and Planning Ministry of Health and Care Services, Oslo 19. February 2009 State secretary Rigmor Aasrud Dear speakers, dear participants,
More informationUniversity of Prince Edward Island PANDEMIC PREPAREDNESS PLAN. October 7, 2009
University of Prince Edward Island PANDEMIC PREPAREDNESS PLAN October 7, 2009 University of Prince Edward Island PANDEMIC PREPAREDNESS PLAN Table of Contents Page 1.0 Introduction 3-6 1.1 Objective 1.2
More informationProgress from the Patient-Centered Outcomes Research Institute (PCORI)
Progress from the Patient-Centered Outcomes Research Institute (PCORI) Anne Beal, Chief Operating Officer of the Patient-Centered Outcomes Research Institute Sharon-Lise Normand, Vice Chair, Methodology
More informationStandardization for Preclinical Evaluation of Influenza Vaccines in Animal Models - WHO activities
Standardization for Preclinical Evaluation of Influenza Vaccines in Animal Models - WHO activities 2 nd WHO Integrated Meeting on development and clinical trials of Influenza vaccines that induce broadly
More informationThe Economic and Social Council, Recalling the United Nations Millennium Declaration13 and the 2005 World Summit Outcome, 1
Resolution 2010/24 The role of the United Nations system in implementing the ministerial declaration on the internationally agreed goals and commitments in regard to global public health adopted at the
More informationIndustry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006
Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine use from high to low income countries since 2006 Dr. Michael Watson, sanofi-pasteur on behalf of WHO GAP
More informationTHE EVOLVING LANDSCAPE OF INFECTION PREVENTION: RISK MITIGATION THROUGH INFECTION SURVEILLANCE
THE EVOLVING LANDSCAPE OF INFECTION PREVENTION: RISK MITIGATION THROUGH INFECTION SURVEILLANCE Yves Crehore Software Product Manager, R.N. RL Solutions AGENDA Current Infectious Landscape Partnership:
More informationTrends and Challenges in Technical and Manufacturing Collaboration. Alex Neverov Vaccine World MENA & CIS NOV 2014
Trends and Challenges in Technical and Manufacturing Collaboration Alex Neverov Vaccine World MENA & CIS 2014 20 NOV 2014 Topics to Cover Identifying Partners Who we are What do our partners share Exploring
More informationH1N1 Vaccine Campaign What worked? California Department of Public Health Immunization Branch
H1N1 Vaccine Campaign What worked? Hurdles and Barriers Frayed pre-pandemic infrastructure for immunization Brief period to construct complex vaccine delivery systems based on readjusted assumptions Vaccine
More informationAPHL Next Generation Sequencing (NGS) Survey
Next Generation Sequencing 1. How long has your lab had a sequencer? [If lab does not have a sequencer go to 1a1 through 1a3 and then end survey] [If lab does have a sequencer continue to 1a and the rest
More informationGAVI, THE VACCINE ALLIANCE
#vaccineswork GAVI, THE VACCINE ALLIANCE Partnerships for Health Outcomes Susan Brown July, 2017, New York Gavi/2012/Doune Porter www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and
More informationApproximately 6 years ago, then-president
Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science Volume 11, Number 2, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/bsp.2013.0042 Commentary The Pandemic and All-Hazards Preparedness
More informationPandemic Influenza: Appropriations for Public Health Preparedness and Response
Order Code RS22576 January 23, 2007 Pandemic Influenza: Appropriations for Public Health Preparedness and Response Summary Sarah A. Lister Specialist in Public Health and Epidemiology Domestic Social Policy
More informationAssociation of Public Health Laboratories
STATEMENT BY DR. Peter A. Shult ON BEHALF OF THE ASSOCIATION OF PUBLIC HEALTH LABORATORIES DIRECTOR OF THE COMMUNICABLE DISEASES DIVISION OF THE WISCONSIN STATE LABORATORY OF HYGIENE ON Beyond the Checklist:
More informationFederal Register / Vol. 72, No. 77 / Monday, April 23, 2007 / Notices
Federal Register / Vol. 72, No. 77 / Monday, April 23, 2007 / Notices 20117 DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Vaccine Advisory Committee AGENCY: Department of Health and Human
More informationGlobal Health Security and Domestic Preparedness:
Centers for Disease Control and Prevention Robert R. Redfield, MD Director, Centers for Disease Control and Prevention Global Health Security and Domestic Preparedness: Public Health in an Insecure World
More information